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Abstract
Background: Individuals infected with the 2009 pandemic virus A(H1N1) developed serological response which can be
measured by hemagglutination-inhibition (HI) and microneutralization (microNT) assays.
Methodology/Principal Findings: MicroNT and HI assays for specific antibody to the 2009 pandemic virus were conducted
in serum samples collected at the end of the first epidemic wave from various groups of Thai people: laboratory confirmed
cases, blood donors and health care workers (HCW) in Bangkok and neighboring province, general population in the North
and the South, as well as archival sera collected at pre- and post-vaccination from vaccinees who received influenza vaccine
of the 2006 season. This study demonstrated that goose erythrocytes yielded comparable HI antibody titer as compared to
turkey erythrocytes. In contrast to the standard protocol, our investigation found out the necessity to eliminate nonspecific
inhibitor present in the test sera by receptor destroying enzyme (RDE) prior to performing microNT assay. The investigation
in pre-pandemic serum samples showed that HI antibody was more specific to the 2009 pandemic virus than NT antibody.
Based on data from pre-pandemic sera together with those from the laboratory confirmed cases, HI antibody titers $40 for
adults and $20 for children could be used as the cut-off level to differentiate between the individuals with or without past
infection by the 2009 pandemic virus.
Conclusions/Significance: Based on the cut-off criteria, the infection rates of 7 and 12.8% were estimated in blood donors
and HCW, respectively after the first wave of the 2009 influenza pandemic. Among general population, the infection rate of
58.6% was found in children versus 3.1% in adults.
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Introduction
There were 3 influenza pandemics occurring in the last century,
i.e., Spanish influenza A (H1N1) in 1918, Asian influenza A
(H2N2) in 1957 and Hong Kong influenza A (H3N2) in 1968 [1].
The influenza pandemic phase of this century, as declared by the
World Health Organization (WHO) on 11
th June 2009, was
caused by A (H1N1) virus [2], a reassortant derived from influenza
viruses of 4 origins: classical swine, European swine, avian, and
human influenza viruses [3]. Epidemiological studies of the 2009
pandemic showed that the disease is more common in children
[4,5]. Death mostly occurred in patients with underlying
conditions, such as pregnancy, obesity, diabetes, hematological
malignancy and cardiopulmonary dysfunction [6–9].
It is necessary to estimate and predict the magnitude of the
pandemic in various regions worldwide, either by case based or
serological based surveillance. However, the serological surveys
were estimated to be approximately 10 times more sensitive than
the clinical surveillance for determining infection rate of the
pandemic virus [10,11]. HI assay employing turkey erythrocytes
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established as the cut-off levels to estimate the infection rates in
populations by various groups of investigators [10–13]. This cut-
off titer was established based on the WHO guideline for vaccine
evaluation which suggested HI antibody titers $40 as the levels
indicating 50% protection [14,15]. Moreover, microNT assay had
been conducted in parallel in order to determine the protection
correlation, and it was suggested that the HI antibody titer 40 was
correlated to the NT titer 160 in adults or 40 in children [13].
On 10
th August 2010, WHO announced the beginning of the
post-pandemic phase of the 2009 pandemic influenza. Neverthe-
less, epidemiological data from the Bureau of Epidemiology of
Thailand suggested that only one fourth of the Thai population
had been infected by this novel virus after it was introduced into
Thailand at the beginning of May 2009 until December 2009. The
data suggested that Southeast Asian countries and some other
parts of the world might still be vulnerable to the new attack by
that time.
The present study aimed to establish the cut-off HI and NT
antibody titers that could differentiate between individuals with or
without past infection by the 2009 pandemic influenza. We
demonstrated that erythrocytes from goose yielded comparable HI
antibody titers as those from turkey, an animal species that is not
common in Southeast Asian countries. Moreover, we showed that
it is necessary to treat human sera with receptor destroying
enzyme (RDE) before running microNT assay. This RDE
treatment is usually not included in the microNT protocol
generally employed for testing human sera in most laboratories
[10,13,16,17]. Our established cut-off titers were applied in the
seroepidemiological surveillance to estimate the infection rate in
different groups of the Thai populations after subsidence of the
first epidemic wave.
Materials and Methods
Ethical issues
This study was approved by two Ethical Committees: Siriraj
Institutional Review Board, Faculty of Medicine Siriraj Hospital,
Mahidol University and the Ministry of Public Health Review
Board. Adult subjects signed in consent form for participation.
With ascent from children subjects, their parents signed the
consent form for them.
Subjects
Serum samples tested in this study were collected from 5 groups
of subjects. The first group comprised 80 patients with 2009
pandemic influenza as confirmed by real time reverse transcrip-
tion- polymerase chain reaction employing the protocol of the US,
Centers for Disease Controls [18]. Part of these patients were sent
for disease diagnosis by the Bureau of Epidemiology, Department
of Disease Control, Ministry of Public Health under public health
emergency service; and part of them were sent anonymously from
the clinic sites under the Southeast Asia Infectious Disease Clinical
Research Network, Thailand. The second group comprised 100
anonymous blood donors of the National Blood Center, the Thai
Red Cross Society, Bangkok. All were bled within the same day in
September 2009. Small aliquots of blood were subjected to anti-
HIV testing; and the leftovers were provided for this study. The
third group comprised 258 healthcare workers (HCW) from two
hospitals: Siriraj Hospital, Bangkok and Thammasat University
Hospital in Pathum Thani, the neighboring province of Bangkok.
These HCW were exposed to patients suspected of the 2009
pandemic influenza and/or to the laboratory confirmed cases
during their duty. The fourth group comprised 222 general
population from two provinces, Chiang Mai (696 km. north from
Bangkok) and Nakhon Si Thammarat (780 km. south from
Bangkok), whose ages were older than 5 years. These two
provinces were selected based on highest numbers of reported
cases in the region; and in each province, the random samples
were collected in the community-based setting during the opinion
survey in a district that high number of cases was reported. The
test samples also included anonymously archival sera collected
during pre-pandemic period from vaccinees whose ages were at
range of 21–49 years. The vaccinees received inactivated influenza
vaccine of the 2006 season which contained 15 mg of hemagglu-
tinin antigen of A/New Caledonia/20/1999(H1N1)-like strain (A/
New Caledonia), A/Wellington/1/2004(H3N2)-like strain, and
B/Shanghai/361/2002-like strain (Government Pharmaceutical
Organization-Merieux Biological Products Co., Ltd., Bangkok).
Details regarding subjects who participated in this study are shown
in Table 1.
Blood samples
Paired bloods were collected from the patients, and single blood
samples were collected from the other groups of subjects. Acute
blood samples were collected mostly within 7 days; meanwhile, the
convalescent samples were collected at between 11 to 54 days after
onset of illness. Serum was separated, aliquot and kept frozen at -
20 C until tested.
Regarding archival sera, the pre-vaccinated blood samples were
collected just before vaccination; and the post-vaccinated blood
samples were collected at one month later.
The study virus
A/Thailand/104/2009(H1N1) propagated in MDCK cells was
used as the test virus for both HI and microNT assays. Full
genomic sequence of this isolate can be retrieved from the
GenBank database. The H genomic sequence of this virus was
99.7% identity to that of A/California/7/2009 pandemic virus
(data not shown).
Reference serum
A reference human serum from the National Institute for
Biological Standards and Control (NIBSC), UK was used for
standardizing our serological methods. Based on the investigation
performed by various laboratories under the International
Collaborative Study, this reference serum had the overall
geometric mean titer (GMT) of 183 by HI and 516 by microNT
assays (NIBSC package insert). The HI GMT titer 183 implies that
the results of HI titers obtained from those laboratories varied
between 160 and 320. Similarly, the NT GMT titer 516 implies
that the results of NT titers varied between 320 and 640.
Hemagglutination (HA) assay
HA assay was performed in order to measure the amount of
hemagglutinin antigen present in the test virus suspension prior to
running HI assay [17]. The test virus was serially twofold diluted
with phosphate buffered saline (PBS) in a volume of 50 ml/well in
duplicate. Fifty ml of 0.5% goose or 0.5% turkey erythrocyte
suspension was added into the test wells and incubated for 30
minutes at 4 C before hemagglutinating result was determined.
One HA unit of the test virus was defined as the highest virus
dilution that displayed complete hemagglutinating activity.
Hemagglutination inhibition (HI) assay
HI assay was performed as previously described [17,19–21].
Fifty ml of the test serum were mixed with 150 ml of RDE (Denka
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C for eliminating the nonspecific inhibitors. This step was followed
by heat inactivation at 56 C for 30 minutes, and removal of
nonspecific agglutinator by absorbing with the test erythrocytes for
1 hour at 4 C. The replicating virus at final concentration of 4 HA
units/25 ml was used as the test antigen; and goose or turkey
erythrocytes were used as the indicator. The treated serum was
twofold serially diluted in duplicate wells of a microtiter V shaped
plate at an initial dilution of 1:10; and 25 ml of the diluted serum
were incubated with 25 ml of the test antigen for 30 minutes at
room temperature. Thereafter, the reaction wells were added with
50 ml of 0.5% goose or 0.5% turkey erythrocyte suspension and
further incubated for 30 minutes at 4 C before the HI antibody
titers were determined. HI antibody titer is defined as the
reciprocal of the highest serum dilution that completely inhibits
hemagglutination reaction. Reference/positive control serum with
known HI titer, the serum control and back titration of virus
antigen were included in each run. For calculating GMT, the
antibody titer ,10 was assigned as 5, and the titer $2560 was
assigned as 2560.
Microneutralization (microNT) assay
ELISA based microNT assay was performed as described
previously [17,19–21]. The test sera were treated by any of the
following two protocols. The first one was the standard protocol
employing only heat inactivation of the native sera at 56 C for 30
minutes; and the second one employed RDE treatment similar to
that mentioned above for HI assay. Briefly, 50 ml of the test serum
were mixed with 150 ml of RDE and incubated overnight in water
bath at 37 C followed by heat inactivation at 56 C for 30 minutes.
The treated sera were twofold serially diluted in duplicate and
incubated with the test virus at final concentration of
100TCID50/100 ml for 2 hours at 37 C. The serum-virus mixture
was transferred onto MDCK monolayer maintained in minimum
essential medium supplemented with trypsin TPCK (Sigma,
St.Louis, MO.) for 24 hours. The reaction plate was tested by
ELISA for presence of the viral nucleoprotein using mouse specific
monoclonal antibody (Chemicon, Temecula, CA.) as the primary
antibody and goat anti-mouse Igs (Southern Biotech, Birmingham,
AL.) as the secondary antibody. Antibody titer is defined as
reciprocal of the highest serum dilution that reduces $50% of the
amount of viral nucleoprotein in the reaction wells as compared to
the virus control wells. For calculating GMT, the antibody titer
,10 was assigned as 5, and the titer $2560 was assigned as 2560.
Results
Goose and turkey erythrocytes yielded comparable HI
antibody titers
In order to determine that goose and turkey erythrocytes
yielded comparable HI antibody titers, the reference human
serum from the NIBSC which contains HI antibody at GMT 183
was assayed in duplicate by 6 scientists using goose and turkey
erythrocytes in parallel experiments. The HI antibody titer 160
was obtained from all 6 scientists as using either one of both
erythrocyte species. The comparison was further extended to
include the acute and convalescent serum samples from 53
patients as well as single serum samples from 100 HCW. The
analysis on the total number of 206 serum samples showed that
goose and turkey erythrocytes yielded comparable HI titers with
r=0.96 (Spearman’s rank, p,0.0001) (Figure 1). The number of
samples with HI antibody titers $40, as well as the ratio between
convalescent to acute antibody titers, and the number of samples
showing a fourfold or greater rise in HI antibody titer, were similar
when goose or turkey erythrocytes were used (Table 2). Based on
comparable HI titers obtained by the two erythrocyte species as
well as our convenience to obtain goose erythrocytes; therefore,
goose erythrocytes were employed in the subsequent experiments
of our HI assay.
RDE treated serum was required for microNT assay
We recognized that microNT assay using RDE untreated sera
yielded an unusually high level of NT antibody to the 2009
pandemic virus in the test sera which had no HI antibody.
Therefore, the serum samples were treated with RDE and retested
again. The result showed that the RDE treated sera from all serum
settings showed a marked decrease in level of NT antibody titer
when compared to the RDE untreated samples (Wilcoxon Signed
Table 1. Subjects and time of specimen collection.
Age (years)
Subjects
No. of
subjects Mean Median Range Time at specimen collection
Vaccinees who received seasonal influenza 71 33.6 31 21–49 Dec 2005 - Mar 2006 (pre-vaccination) Jan - Apr
2006 (post-vaccination)
Patients
- Pediatrics 36 10.6 12.5 2–15 June 2009 – Feb 2010
- Adults 44 23.6 21 18–62 June 2009 – Feb 2010
Blood donors 100 35.7 34.5 17–60 Sep 2009
Health care workers 258 35.3 34 20–61 Oct 2009
General population (Chiang Mai)
- Children 11 9.8 10 7–13 Dec 2009
- Adults 99 49.3 52 15–89 Dec 2009
General population (Nakhon Si Thammarat)
- Children 18 10.1 10.5 5–14 Dec 2009
- Adults 94 49.5 48 15–87 Dec 2009
doi:10.1371/journal.pone.0016164.t001
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were employed subsequently.
Moreover, the reference human serum from NIBSC which
harbored NT antibody at GMT 516 was assayed in parallel by our
two scientists using RDE treated serum as well as the untreated
serum control in triplicate experiments. The GMT 640 was
obtained either with the RDE treated or untreated serum.
Cross-reactive antibody to the 2009 pandemic virus in
pre-pandemic serum samples
Information about serological response in our vaccinees who
received influenza vaccines during the pre-pandemic period had
been published previously [22]. Among 71 tested sera, 98.6%
developed a fourfold or greater rise in HI antibody titer against A/
New Caledonia, a component of the immunizing vaccine (Table 4).
Herein, those serum samples were investigated for serological
response against the 2009 pandemic virus; and it was found that
16.9% of the vaccinees developed seroconversion as determined
by HI assay. Six (8.4%) subjects seroconverted with HI titer rising
from #10 to $40. Cross-reactive HI antibody titer 80 was found
in one (1.4%) pre-vaccinated serum sample; nevertheless, post-
vaccinated serum from this subject did not increase in antibody
titer against the 2009 pandemic virus. At post-vaccination, number
of subjects with the cross-reactive HI antibody $40 increased to 8
(11.3%). Regarding microNT assay, 16 (22.5%) developed a
fourfold or greater rise in antibody titer (convalescent titer $40) in
post-vaccination sera. Our study demonstrated broader cross-
reactivity of NT antibody than HI antibody.
HI and NT antibody response in patients infected with
the 2009 pandemic influenza virus
HI and NT antibody response in the patients by days after onset
of illness is shown in Figure 2. Positive correlation with r=0.85
(Spearman’s rank, p,0.0001) was found between the two assays.
Seroconversion or a fourfold or greater rise in HI or NT antibody
titers could be demonstrated when convalescent blood samples
were collected at 11 days earliest after disease onset. Among 36
pediatric cases, 32 (88.9%) developed seroconversion (Table 5).
The other 4 cases already contained high HI titers $40 in their
first blood samples. And among 32 seroconverters, 5 cases (13.9%)
seroconverted with HI titers rising from ,10 to 20; and the
remaining 29 cases seroconverted with convalescent titers $40.
Therefore, the HI titers $20 were found in 100%, and HI titer
$40 were found in 86.1% of the pediatric patients. Similarly, the
NT titers $20 were found in 97.2% and NT titer $40 were found
in 94.4%.
Among 44 adult patients, 43 (97.7%), developed HI titers $40
in their convalescent sera. There was one adult patient who could
not develop significant HI antibody response (HI titer ,10 and
10), although he possessed NT antibody titer of 20 and 80. The
convalescent NT titers $80 were found in all adult patients.
Estimation of the infection rate of the 2009 pandemic
influenza after the first epidemic wave
Regarding titers of HI antibody found in the patients together
with the data showing the absence of HI antibody in all except one
pre-pandemic serum samples, the cut-off HI antibody titers $20
for pediatric cases and $40 for adult patients were established to
indicate past infection by the 2009 pandemic virus. The
established criteria had been used to estimate the infection rate
of the 2009 pandemic influenza in various groups of populations;
Figure 1. Correlation between HI antibody titers obtained from
goose and turkey erythrocytes by HI assays.
doi:10.1371/journal.pone.0016164.g001
Table 2. Comparison between HI antibody titers obtained from goose and turkey erythrocytes.
Subjects HI assay with Number of sera test Blood GMT (95% CI)
No. with HI titers
$40
No. with 4-fold
rising Ab titer (%)
Ratio Conv./
Acute
Patients 0.5% turkey RBC Children =29 Acute 14 (8–25) 7
Convalescent 111 (78–158) 28 23 (79.3) 7.6
Adults =24 Acute 15 (7–29) 6
Convalescent 87 (53–141) 22 19 (79.2) 5.8
0.5% goose RBC Children =29 Acute 15 (8–27) 8
Convalescent 106 (72–157) 27 24 (82.8) 6.9
Adults =24 Acute 14 (7–28) 6
Convalescent 89 (55–145) 22 19 (79.2) 6.4
Health care
workers
0.5% turkey RBC Adults =100 Single blood 9 (7–10) 14 NA NA
0.5% goose RBC Adults =100 Single blood 9 (7–11) 15 NA NA
Note: A/Thailand/104/2009(H1N1) was used as the test virus. GMT = geometric mean titer, CI = confidence intervals, RBC = red blood cells,
NA = Not applicable
doi:10.1371/journal.pone.0016164.t002
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had been infected with the pandemic virus by the end of the first
epidemic wave (Table 6). Magnitude of the infection in the general
population residing in the North and the South of Thailand was
similar. In these two populations, the infection rates were much
higher in children (17 of 29) than adults (6 of 193), i.e., 58.6 versus
3.1%, respectively.
It was not easy to establish the cut-off NT antibody titer owing
to presence of cross-reactive NT antibody at high titers in the pre-
pandemic serum samples collected from vaccinees whose ages
were under 50 years, and also in general people who had no HI
antibody against the 2009 pandemic virus. Poorer correlation
between HI and NT antibody was found in this group of subject
(r=0.32: Spearman’s rank, p,0.0001) (data not shown).
Discussion
Herein, HI and microNT assays that were suitable for a
Southeast Asian country had been established to estimate the
infection rate of the 2009 pandemic influenza in Thai people after
subsidence of the first epidemic wave. HI assay has long been used
for serodiagnosis of influenza virus infection, vaccine evaluation,
and vaccine strain selection [16,23,24]. It was noted that sensitivity
of the HI assay could be affected by the erythrocyte species
Table 3. Comparison between NT antibody titers obtained from RDE treated and RDE untreated sera.
Number of cases at NT antibody of
Subjects
No. of
subjects Blood samples
RDE
treatment ,10 10 20 40 80 160 320 640 $1280 GMT* (95% CI)
Patients 80 Acute Yes 9 30 8 3 8 12 3 4 3 33 (23–47)
No 0 0 0 7 18 21 22 5 7 191 (155–236)
80 Convalescent Yes 0 1 1 3 14 23 22 9 7 214 (172–267)
No 0 0 0 1 2 11 36 22 8 380 (326–443)
General
population
222 Single blood Yes 15 87 46 33 24 10 5 2 0 21 (18–24)
No 0 0 0 103 88 22 5 3 1 66 (61–72)
Vaccinees 71 Pre-vaccination Yes 22 34 6 7 0 1010 1 0 ( 8 – 1 3 )
No 0 0 1 5 33 27 2 3 0 110 (95–127)
71 Post-vaccination Yes 3 19 24 16 6 1111 2 3 ( 1 8 – 2 8 )
N o 00002 4 3 4 841 1 5 2 ( 1 3 1 – 1 7 6 )
Blood donors 100 Single blood Yes 10 40 19 16 6 7200 1 9 ( 1 6 – 2 4 )
No 0 0 0 1 29 60 10 0 0 138 (126–150)
Health care
workers
258 Single blood Yes 14 116 61 35 15 12 1 4 0 19 (16–21)
No 0 0 0 10 81 127 34 5 1 138 (129–148)
*There are significant differences between GMT of NT antibodies in RDE treated and untreated sera from all 7 serum settings (Wilcoxon Signed Ranks test, p,0.05).
doi:10.1371/journal.pone.0016164.t003
Table 4. Cross-reactive antibody to the 2009 pandemic A (H1N1) influenza virus in vaccinees who received trivalent influenza
vaccine of the 2006 season (N=71).
Number of cases with antibody titer of
Test viruses Assays ,10 10 20 40 80 160 320 640 GMT (95% CI)
Post- to pre-
vaccination ratio
No. with $4 folded
rise in Ab titer
a (%)
A/New Caledonia/20/99-like
(H1N1)
Pre-vaccination HI 43 8 9 10 0 0 1 0 9 (7–11)
Post-vaccination HI 0 0 1181 31 53 33 1 0 ( 2 5 4 – 3 7 9 )3 4 7 0 ( 9 8 . 6 )
b
A/Thailand/104/09 (H1N1)
Pre-vaccination HI 64 5 1010 0 0 5 (5–6)
Post-vaccination HI 43 12 8232 1 0 9 (7–11) 2 6 (8.4)
Pre-vaccination microNT 22 34 6701 0 1 1 0 ( 8 – 1 3 )
Post-vaccination microNT 3 19 24 16 6 1 1 1 23 (18–28) 2 16 (22.5)
aSeroconversion with post-vaccination antibody titer $40 to the 2009 pandemic virus.
bA/New Caledonia/20/99 was used as the test antigen.
doi:10.1371/journal.pone.0016164.t004
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erythrocytes were more sensitive than turkey erythrocytes in the
detection of HI antibody to H5N1 highly pathogenic avian
influenza (HPAI) virus. Since there was difficulty in accessing both
horse and turkey erythrocytes in Thailand, we previously looked
for the alternative erythrocyte species and found that goose
erythrocytes yielded comparable results in both HA and HI assays
[19]. Similarly, the present study showed that goose erythrocytes
could replace turkey erythrocytes for detection of HI antibody to
the 2009 pandemic influenza virus. Our preliminary study on 206
serum samples as well as the reference serum from NIBSC
demonstrated good correlation between HI titers employing either
goose or turkey erythrocytes. This finding is an advantage for
laboratories in Southeast Asian countries where goose erythrocytes
have long been used in HI assay for diagnosis of dengue,
chikungunya and Japanese encephalitis, the endemic diseases in
this region. It was also demonstrated that the hemagglutination
pattern of goose was also clearer than that of turkey erythrocytes.
A number of laboratories performed microNT in adjunct with
HI assay in a seroepidemiological study, but the step of serum
treatment with RDE was not included [10,13]. In contrast, our
study showed that NT GMT titer in the test sera without RDE
treatment was significantly higher than that employed the RDE
treated sera. Collectively, RDE is used for removal of nonspecific
inhibitor from the test sera, in which its presence may lead to false
positive result in HI as well as microNT assays as shown by this
study. On the other hand, the presence of this nonspecific inhibitor
did not affect our result on using RDE untreated sera in microNT
assay for antibody against H5N1 HPAI virus. Cross-reactive
H5N1 antibody, even at low level, was rare [20,21,26]. Therefore,
Figure 2. Antibody titers by date after onset of symptom. (A) HI antibody titer; (B) NT antibody titer. Colored stacked bars give the proportion
with titers of 10, 20, 40 and $80 while the line denotes the geometric mean titer with error bars indicating 95% confidence intervals.
doi:10.1371/journal.pone.0016164.g002
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bind to different species of nonspecific inhibitor.
Investigation in pre-pandemic serum samples demonstrated that
NT antibody is broader in activity than HI antibody; however,
both cross-reactive HI and NT titers could be increased by
seasonal influenza vaccination. Similarly, Hancock, et al. [13]
previously reported a fourfold or greater increase in cross-reactive
antibody to the 2009 pandemic virus in archival serum samples
from adult recipients of trivalent inactivated influenza vaccines
during 2007–2009 seasons. A fourfold or greater increase in cross-
reactive HI antibody was found in 7% among vaccinees of age 18–
64 years, but it was as high as 22% for cross-reactive NT antibody.
This cross- reactive antibody was rarely found in young children in
their study. Our group previously reported that 5.2% of the elderly
who received seasonal influenza vaccine seroconverted to HPAI
H5N1 virus as determined by microNT assay [27]. Nevertheless,
the studies from U.S. and Australia concluded that vaccination
with seasonal influenza vaccine did not protect against the current
pandemic [13,28]. In contrast, partial protection conferred
through seasonal influenza vaccination was reported by the other
group of investigators [29]. Frequency of cross-reactive NT
antibody was high in Thai and U.S. population [13]; and it was
as low as 0.3% in Chinese [12]. However, it is well accepted that
NT antibody activity is broader than HI antibody. HI antibody
recognizes small epitopes in erythrocyte binding site, while NT
antibodies recognize the epitopes in HA1 variable domain of the
Table 5. HI and NT antibody response in patients infected with the 2009 pandemic influenza virus.
No. of cases at antibody titer of
Patients Assays
Blood
samples ,10 10 20 40 80 160 320 640 1280 2560
GMT
(95% CI)
Ratio of
Conv./Acute
No. with $4
folded rise in
Ab titers (%)
Children
(N=36)
H I A c u t e 1 981213 2 0 0 0 1 2 ( 7 – 1 9 )
Conv. 0 0 5 12 10 3 1 4 1 0 78 (53–114) 6.3 32 (88.9%)
m i c r o N T A c u t e 5 2 0 2153 0 0 0 0 1 6 ( 1 1 – 2 3 )
Conv. 0 1 1396 8 4 4 0 1 7 9 ( 1 1 9 – 2 6 9 ) 1 0 . 9 3 1 ( 8 6 . 1 % )
Adults
(N=44)
H I A c u t e 1 544385 2 2 1 0 2 9 ( 1 7 – 4 8 )
Conv. 0 1 0 16 15 6 3 2 1 0 83 (63–111) 38.1 24 (54.5%)
m i c r o N T A c u t e 4 1 0 6239 3 4 2 1 5 8 ( 3 3 – 1 0 0 )
Conv. 0 0 0051 71 45 3 0 2 4 8 ( 1 9 9 – 3 1 0 ) 4 . 3 2 3 ( 5 2 . 3 % )
Note: Number of pediatric patients with convalescent HI titers $20=36/36 (100.0%).
Number of adult patients with convalescent HI titers $40=43/44 (97.7%).
doi:10.1371/journal.pone.0016164.t005
Table 6. Estimation on the infection rates of the 2009 pandemic influenza in different groups of subjects after the first epide mic
wave.
No. of cases at antibody titer of
Subjects Assays ,10 10 20 40 80 160 320 640
Infection
rate (%) GMT (95% CI)
Blood donors (N=100) H I 8 1757000 0 7 (7.0) 6 (5–7)
microNT 10 40 19 16 6 7 2 0 19 (16–24)
Health care workers (N=258) HI 177 26 22 16 12 5 0 0 33 (12.8) 8 (7–9)
microNT 14 116 61 35 15 12 1 4 19 (16–21)
General population (Chiang Mai, N=110)
- C h i l d r e n ( N = 1 1 ) H I 2 014220 0 9 ( 8 1 . 8 ) 3 7 ( 1 7 – 8 2 )
- A d u l t s ( N = 9 9 ) H I 8 6823000 0 3 (3.0) 5 (5–6)
- C h i l d r e n ( N = 1 1 ) m i c r o N T 0 110223 2 1 4 1 ( 5 7 –348)
- Adults (N=99) microNT 2 40 24 16 11 4 2 0 22 (18–26)
General population (Nakhon Si Thammarat, N=112)
- C h i l d r e n ( N = 1 8 ) H I 1 0022400 0 8 ( 4 4 . 4 ) 1 3 (7–24)
- A d u l t s ( N = 9 4 ) H I 8 1643000 0 3 (3.2) 5 (5–6)
- C h i l d r e n ( N = 1 8 ) m i c r o N T 2 742120 0 1 9 ( 1 1 – 3 2 )
- Adults (N=94) microNT 11 39 17 15 10 2 0 0 17 (14–20)
Infection rate is determined by HI titer $40 in adults or $20 in children.
doi:10.1371/journal.pone.0016164.t006
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which is conserved across influenza A subtypes [30–32].
Only one (2.3%) of our 44 adult patients failed to mount HI
antibody titers $40 in their convalescent blood. Meanwhile,
Miller, et al [10] demonstrated that HI assay failed to diagnose
10.9% of laboratory confirmed cases in their setting as the cut-off
point $32 was employed. According to Millers, et al, the adult and
pediatric patients were not separately analyzed; and the HI titers
32 or greater were found in 89.1% of their patients. In our study, if
the data from pediatric and adult patients was pooled and
analyzed together, the HI titer 40 or greater will be found in
92.5% of our patients. Regarding the study by Chen, et al [33], the
HI titers 40 or greater were found in 93% of their adult patients if
the convalescent blood samples were collected at peak between 25
and 29 days after onset of symptom.
Our study decided to use the HI antibody at cut-off titers $40
for adults and $20 for children to differentiate between
individuals with and without past infection by the 2009 pandemic
influenza. The cut-off titer for NT antibody could not be
established because frequency of the cross-reactive NT titers was
high as shown from the result of investigation in pre-pandemic
sera obtained from vaccinees of age younger than 50 years, and
additionally, from the high number of general adult population
who had no HI antibody, but possessed NT titer $40. Based on
our criteria, magnitudes of the 2009 pandemic influenza after the
first epidemic wave were around 7% in blood donors and 12.8%
in HCW. Eventually, the infection rate in general population was
much higher in children than adults, i.e., 58.6% (17/29) versus
3.1% (6/193), which is suggestive of susceptibility of children and
partial protection from pre-existing immunity in Thai adults. In
United Kingdom, seroincidence rate of the 2009 pandemic
influenza was also high in children [10]. Seroepidemiological
data from Pittsburgh, U.S. showed that approximately 21% of
population was infected following the second epidemic wave [34].
Estimation on the infection rates based on serological data may be
affected by confounding factor of cross-reactive antibody-rising
from seasonal influenza vaccination; and probably from pre-
existing antibody against the 1957 influenza A (H1N1) virus.
Nevertheless, this effect may be not drastic in the Thai population
owing to less than 1% coverage of seasonal influenza vaccination
among the Thai population. In addition, most of our adult subjects
were younger than 50 years, therefore, cross-reactive antibody
owing to previous infection by the 1918 influenza A (H1N1) virus
was excluded.
Thailand reported the first two imported cases from Mexico in
the beginning of May 2009. Subsequently, the virus was re-
introduced into the country both by groups of tourists and Thai
students who returned from Europe and America. The first
epidemic wave began in late May, peaked in July and almost
disappeared in November 2009. The first wave was followed by a
short period of the second epidemic wave during December 2009
to April 2010 with peak in February. The third epidemic wave
which lasted between June and October with peak in August 2010
was more serious than the second one. Serosurveillance nation-
wide will help the estimation for number of vulnerable people and
immunity of the population to this pandemic virus. The 2009
pandemic monovalent vaccine was introduced into Thailand in
December 2009; and trivalent vaccine containing the 2009
pandemic virus as a component has been introduced into the
country in June 2010. Nevertheless, the vaccine coverage was less
than 3% of the Thai population. Therefore, cross-reactive HI
antibody due to the pandemic virus might have least effect on the
estimated infection rate in the present study.
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